nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.166	0.456	CbGbCtD
Anagrelide—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.133	0.365	CbGbCtD
Anagrelide—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0649	0.179	CbGbCtD
Anagrelide—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000303	0.000476	CcSEcCtD
Anagrelide—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000476	CcSEcCtD
Anagrelide—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000302	0.000474	CcSEcCtD
Anagrelide—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000301	0.000473	CcSEcCtD
Anagrelide—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000299	0.000469	CcSEcCtD
Anagrelide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000297	0.000467	CcSEcCtD
Anagrelide—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000467	CcSEcCtD
Anagrelide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000296	0.000465	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000295	0.000464	CcSEcCtD
Anagrelide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000293	0.000461	CcSEcCtD
Anagrelide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000293	0.00046	CcSEcCtD
Anagrelide—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.00046	CcSEcCtD
Anagrelide—Pain—Cisplatin—peripheral nervous system neoplasm	0.000292	0.000459	CcSEcCtD
Anagrelide—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000289	0.000454	CcSEcCtD
Anagrelide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000288	0.000452	CcSEcCtD
Anagrelide—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000449	CcSEcCtD
Anagrelide—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000449	CcSEcCtD
Anagrelide—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000286	0.000449	CcSEcCtD
Anagrelide—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000285	0.000448	CcSEcCtD
Anagrelide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000284	0.000446	CcSEcCtD
Anagrelide—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000443	CcSEcCtD
Anagrelide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000282	0.000443	CcSEcCtD
Anagrelide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000281	0.000442	CcSEcCtD
Anagrelide—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000281	0.000442	CcSEcCtD
Anagrelide—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.00044	CcSEcCtD
Anagrelide—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000279	0.000439	CcSEcCtD
Anagrelide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000279	0.000439	CcSEcCtD
Anagrelide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000279	0.000438	CcSEcCtD
Anagrelide—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000437	CcSEcCtD
Anagrelide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000277	0.000436	CcSEcCtD
Anagrelide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000277	0.000435	CcSEcCtD
Anagrelide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000275	0.000432	CcSEcCtD
Anagrelide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000432	CcSEcCtD
Anagrelide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000275	0.000431	CcSEcCtD
Anagrelide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000273	0.000429	CcSEcCtD
Anagrelide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000272	0.000428	CcSEcCtD
Anagrelide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000426	CcSEcCtD
Anagrelide—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000425	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00027	0.000425	CcSEcCtD
Anagrelide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00027	0.000425	CcSEcCtD
Anagrelide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00027	0.000424	CcSEcCtD
Anagrelide—Pain—Etoposide—peripheral nervous system neoplasm	0.000268	0.000421	CcSEcCtD
Anagrelide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000268	0.000421	CcSEcCtD
Anagrelide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000421	CcSEcCtD
Anagrelide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000421	CcSEcCtD
Anagrelide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.00042	CcSEcCtD
Anagrelide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000265	0.000417	CcSEcCtD
Anagrelide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000265	0.000416	CcSEcCtD
Anagrelide—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000264	0.000415	CcSEcCtD
Anagrelide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000415	CcSEcCtD
Anagrelide—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000412	CcSEcCtD
Anagrelide—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.00041	CcSEcCtD
Anagrelide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000409	CcSEcCtD
Anagrelide—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000409	CcSEcCtD
Anagrelide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000408	CcSEcCtD
Anagrelide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000259	0.000406	CcSEcCtD
Anagrelide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000258	0.000406	CcSEcCtD
Anagrelide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000258	0.000406	CcSEcCtD
Anagrelide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000257	0.000404	CcSEcCtD
Anagrelide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000403	CcSEcCtD
Anagrelide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000256	0.000402	CcSEcCtD
Anagrelide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000256	0.000402	CcSEcCtD
Anagrelide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000255	0.000401	CcSEcCtD
Anagrelide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.000398	CcSEcCtD
Anagrelide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.000397	CcSEcCtD
Anagrelide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000251	0.000395	CcSEcCtD
Anagrelide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000393	CcSEcCtD
Anagrelide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000249	0.000391	CcSEcCtD
Anagrelide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000248	0.00039	CcSEcCtD
Anagrelide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000389	CcSEcCtD
Anagrelide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000248	0.000389	CcSEcCtD
Anagrelide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000248	0.000389	CcSEcCtD
Anagrelide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000389	CcSEcCtD
Anagrelide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000389	CcSEcCtD
Anagrelide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000388	CcSEcCtD
Anagrelide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000247	0.000388	CcSEcCtD
Anagrelide—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000246	0.000386	CcSEcCtD
Anagrelide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000246	0.000386	CcSEcCtD
Anagrelide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000245	0.000385	CcSEcCtD
Anagrelide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000245	0.000385	CcSEcCtD
Anagrelide—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000384	CcSEcCtD
Anagrelide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000384	CcSEcCtD
Anagrelide—Rash—Vincristine—peripheral nervous system neoplasm	0.000244	0.000383	CcSEcCtD
Anagrelide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000244	0.000383	CcSEcCtD
Anagrelide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000383	CcSEcCtD
Anagrelide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000382	CcSEcCtD
Anagrelide—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000243	0.000382	CcSEcCtD
Anagrelide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000381	CcSEcCtD
Anagrelide—Headache—Vincristine—peripheral nervous system neoplasm	0.000242	0.000381	CcSEcCtD
Anagrelide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000379	CcSEcCtD
Anagrelide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000378	CcSEcCtD
Anagrelide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.000376	CcSEcCtD
Anagrelide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000238	0.000375	CcSEcCtD
Anagrelide—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000374	CcSEcCtD
Anagrelide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000234	0.000368	CcSEcCtD
Anagrelide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000231	0.000363	CcSEcCtD
Anagrelide—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.00023	0.000362	CcSEcCtD
Anagrelide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.00023	0.000361	CcSEcCtD
Anagrelide—Nausea—Vincristine—peripheral nervous system neoplasm	0.00023	0.000361	CcSEcCtD
Anagrelide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000229	0.00036	CcSEcCtD
Anagrelide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00036	CcSEcCtD
Anagrelide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000359	CcSEcCtD
Anagrelide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000359	CcSEcCtD
Anagrelide—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.000358	CcSEcCtD
Anagrelide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000227	0.000357	CcSEcCtD
Anagrelide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000355	CcSEcCtD
Anagrelide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000354	CcSEcCtD
Anagrelide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000225	0.000353	CcSEcCtD
Anagrelide—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000353	CcSEcCtD
Anagrelide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000352	CcSEcCtD
Anagrelide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000223	0.00035	CcSEcCtD
Anagrelide—Chills—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000348	CcSEcCtD
Anagrelide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000222	0.000348	CcSEcCtD
Anagrelide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000347	CcSEcCtD
Anagrelide—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000346	CcSEcCtD
Anagrelide—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000343	CcSEcCtD
Anagrelide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000217	0.000342	CcSEcCtD
Anagrelide—Rash—Cisplatin—peripheral nervous system neoplasm	0.000216	0.000339	CcSEcCtD
Anagrelide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000215	0.000338	CcSEcCtD
Anagrelide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000338	CcSEcCtD
Anagrelide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000214	0.000337	CcSEcCtD
Anagrelide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000336	CcSEcCtD
Anagrelide—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000213	0.000335	CcSEcCtD
Anagrelide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000333	CcSEcCtD
Anagrelide—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000212	0.000333	CcSEcCtD
Anagrelide—Tension—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000332	CcSEcCtD
Anagrelide—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000328	CcSEcCtD
Anagrelide—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000327	CcSEcCtD
Anagrelide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000207	0.000325	CcSEcCtD
Anagrelide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000325	CcSEcCtD
Anagrelide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000324	CcSEcCtD
Anagrelide—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000322	CcSEcCtD
Anagrelide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000321	CcSEcCtD
Anagrelide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000203	0.000319	CcSEcCtD
Anagrelide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000203	0.000319	CcSEcCtD
Anagrelide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000318	CcSEcCtD
Anagrelide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000314	CcSEcCtD
Anagrelide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000199	0.000313	CcSEcCtD
Anagrelide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000313	CcSEcCtD
Anagrelide—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000312	CcSEcCtD
Anagrelide—Rash—Etoposide—peripheral nervous system neoplasm	0.000198	0.00031	CcSEcCtD
Anagrelide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000197	0.00031	CcSEcCtD
Anagrelide—Headache—Etoposide—peripheral nervous system neoplasm	0.000196	0.000308	CcSEcCtD
Anagrelide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.000308	CcSEcCtD
Anagrelide—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000307	CcSEcCtD
Anagrelide—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000305	CcSEcCtD
Anagrelide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000304	CcSEcCtD
Anagrelide—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000303	CcSEcCtD
Anagrelide—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000303	CcSEcCtD
Anagrelide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000301	CcSEcCtD
Anagrelide—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000299	CcSEcCtD
Anagrelide—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000297	CcSEcCtD
Anagrelide—Cough—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000295	CcSEcCtD
Anagrelide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.000295	CcSEcCtD
Anagrelide—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000293	CcSEcCtD
Anagrelide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000186	0.000292	CcSEcCtD
Anagrelide—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000292	CcSEcCtD
Anagrelide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.00029	CcSEcCtD
Anagrelide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000289	CcSEcCtD
Anagrelide—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000288	CcSEcCtD
Anagrelide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000288	CcSEcCtD
Anagrelide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000288	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000286	CcSEcCtD
Anagrelide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000284	CcSEcCtD
Anagrelide—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000282	CcSEcCtD
Anagrelide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000281	CcSEcCtD
Anagrelide—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000281	CcSEcCtD
Anagrelide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000278	CcSEcCtD
Anagrelide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000276	CcSEcCtD
Anagrelide—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000276	CcSEcCtD
Anagrelide—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000275	CcSEcCtD
Anagrelide—Infection—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000274	CcSEcCtD
Anagrelide—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000273	CcSEcCtD
Anagrelide—Shock—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000271	CcSEcCtD
Anagrelide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.000271	CcSEcCtD
Anagrelide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000271	CcSEcCtD
Anagrelide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000172	0.00027	CcSEcCtD
Anagrelide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.00027	CcSEcCtD
Anagrelide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000269	CcSEcCtD
Anagrelide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000171	0.000268	CcSEcCtD
Anagrelide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000267	CcSEcCtD
Anagrelide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000266	CcSEcCtD
Anagrelide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000266	CcSEcCtD
Anagrelide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000266	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000264	CcSEcCtD
Anagrelide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000263	CcSEcCtD
Anagrelide—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000263	CcSEcCtD
Anagrelide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.00026	CcSEcCtD
Anagrelide—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000258	CcSEcCtD
Anagrelide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000257	CcSEcCtD
Anagrelide—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000255	CcSEcCtD
Anagrelide—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000254	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000251	CcSEcCtD
Anagrelide—Shock—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000251	CcSEcCtD
Anagrelide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.00025	CcSEcCtD
Anagrelide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.00025	CcSEcCtD
Anagrelide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000159	0.00025	CcSEcCtD
Anagrelide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000249	CcSEcCtD
Anagrelide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000158	0.000248	CcSEcCtD
Anagrelide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000248	CcSEcCtD
Anagrelide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000247	CcSEcCtD
Anagrelide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000246	CcSEcCtD
Anagrelide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000156	0.000245	CcSEcCtD
Anagrelide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000243	CcSEcCtD
Anagrelide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000155	0.000243	CcSEcCtD
Anagrelide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000153	0.00024	CcSEcCtD
Anagrelide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000239	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000238	CcSEcCtD
Anagrelide—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000238	CcSEcCtD
Anagrelide—Pain—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000236	CcSEcCtD
Anagrelide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000236	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000233	CcSEcCtD
Anagrelide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000231	CcSEcCtD
Anagrelide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000229	CcSEcCtD
Anagrelide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000228	CcSEcCtD
Anagrelide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000227	CcSEcCtD
Anagrelide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000227	CcSEcCtD
Anagrelide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000226	CcSEcCtD
Anagrelide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000225	CcSEcCtD
Anagrelide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000222	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.00022	CcSEcCtD
Anagrelide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.00022	CcSEcCtD
Anagrelide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000219	CcSEcCtD
Anagrelide—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000218	CcSEcCtD
Anagrelide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000218	CcSEcCtD
Anagrelide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000218	CcSEcCtD
Anagrelide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000218	CcSEcCtD
Anagrelide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00021	CcSEcCtD
Anagrelide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000209	CcSEcCtD
Anagrelide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000203	CcSEcCtD
Anagrelide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000202	CcSEcCtD
Anagrelide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000202	CcSEcCtD
Anagrelide—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000198	CcSEcCtD
Anagrelide—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000195	CcSEcCtD
Anagrelide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000189	CcSEcCtD
Anagrelide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000183	CcSEcCtD
Anagrelide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000182	CcSEcCtD
Anagrelide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000181	CcSEcCtD
Anagrelide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000175	CcSEcCtD
Anagrelide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000175	CcSEcCtD
Anagrelide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000174	CcSEcCtD
Anagrelide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000174	CcSEcCtD
Anagrelide—Headache—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000173	CcSEcCtD
Anagrelide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000169	CcSEcCtD
Anagrelide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000164	CcSEcCtD
Anagrelide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000162	CcSEcCtD
Anagrelide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000161	CcSEcCtD
Anagrelide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000161	CcSEcCtD
Anagrelide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.00016	CcSEcCtD
Anagrelide—Nausea—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000152	CcSEcCtD
